Multidisciplinary Lysosomal Program News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Multidisciplinary Lysosomal Program. Real-time updates on events, politics, business and more.

Additional Positive Interim Data from Phase I/II Trial of REGENXBIO'S RGX-111 for the Treatment of Severe MPS I Presented at WORLDSymposium™

February 24, 2023

RGX-111 is an investigational AAV Therapeutic for the treatment of severe MPS I that is part of REGENXBIOs clinical-stage pipeline of neurodegenerative...

United States Ray Wang Dana Cormack Chris Brinzey University Of California Multidisciplinary Lysosomal Program

Source: prnewswire.com

REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposium™ 2022

February 9, 2022

/PRNewswire/ -- RGX-111, a potential one-time gene therapy for MPS I, is well-tolerated across two dose levels, with no drug-related serious adverse events...

United States Ray Wang Dana Cormack Chris Brinzey Steve Pakola University Of California

Source: prnewswire.com

REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposium™ 2022

February 9, 2022

/PRNewswire/ -- RGX-111, a potential one-time gene therapy for MPS I, is well-tolerated across two dose levels, with no drug-related serious adverse events...

United States Ray Wang Dana Cormack Chris Brinzey Steve Pakola University Of California

Source: prnewswire.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Multidisciplinary Lysosomal Program News Today

Additional Positive Interim Data from Phase I/II Trial of REGENXBIO'S RGX-111 for the Treatment of Severe MPS I Presented at WORLDSymposium&#x2122;

REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposium&#x2122; 2022

REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposium&#x2122; 2022

Explore More Categories

Additional Positive Interim Data from Phase I/II Trial of REGENXBIO'S RGX-111 for the Treatment of Severe MPS I Presented at WORLDSymposium™

REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposium™ 2022

REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposium™ 2022